VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 226 filers reported holding VAXCYTE INC in Q4 2023. The put-call ratio across all filers is 0.39 and the average weighting 0.4%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $13,437 | -14.2% | 177,952 | -22.4% | 0.00% | -20.0% |
Q1 2024 | $15,660 | +23.6% | 229,252 | +13.7% | 0.01% | 0.0% |
Q4 2023 | $12,667 | +45.8% | 201,698 | +18.4% | 0.01% | 0.0% |
Q3 2023 | $8,688 | +71.4% | 170,412 | +67.9% | 0.01% | +66.7% |
Q2 2023 | $5,069 | +46.7% | 101,508 | +10.1% | 0.00% | +50.0% |
Q1 2023 | $3,456 | -36.7% | 92,205 | -19.0% | 0.00% | 0.0% |
Q4 2022 | $5,459 | -99.6% | 113,852 | +89.8% | 0.00% | 0.0% |
Q3 2022 | $1,440,000 | +2382.8% | 59,999 | +2167.5% | 0.00% | – |
Q2 2022 | $58,000 | -95.2% | 2,646 | -94.7% | 0.00% | -100.0% |
Q1 2022 | $1,202,000 | – | 49,800 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |